Carl Zeiss Meditec (AFX) Stock Forecast & Price Target

Compare

122 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AFX Analyst Ratings

Hold

0 Buy

9 Hold

1 Sell

Based on 10 analysts giving stock ratings to

Carl

Zeiss Meditec

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AFX Stock 12 Month Forecast

Average Price Target

€39.46

▲(43.18% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Carl Zeiss Meditec in the last 3 months. The average price target is €39.46 with a high forecast of €53.00 and a low forecast of €31.00. The average price target represents a 43.18% change from the last price of €27.56.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"€26","61":"€61","34.75":"€34.8","43.5":"€43.5","52.25":"€52.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":53,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€53.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39.46,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€39.46</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€31.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[26,34.75,43.5,52.25,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.84,29.775384615384617,31.71076923076923,33.646153846153844,35.581538461538464,37.51692307692308,39.45230769230769,41.387692307692305,43.323076923076925,45.25846153846154,47.19384615384615,49.12923076923077,51.06461538461539,{"y":53,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.84,28.733846153846155,29.627692307692307,30.521538461538462,31.415384615384617,32.309230769230766,33.20307692307692,34.096923076923076,34.99076923076923,35.88461538461539,36.77846153846154,37.6723076923077,38.566153846153846,{"y":39.46,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.84,28.083076923076923,28.326153846153847,28.56923076923077,28.81230769230769,29.055384615384614,29.298461538461538,29.54153846153846,29.784615384615385,30.02769230769231,30.270769230769233,30.513846153846153,30.756923076923076,{"y":31,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":58.51,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":59.501,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.75,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.1,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.85,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.45,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.26,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.56,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.44,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.9,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.32,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.84,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€53.00

Average Price Target€39.46

Lowest Price Target€31.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Jonathon Unwin

Barclays

€49→€32

Hold

16.11%

Upside

Downgraded

02/02/26

Carl Zeiss Meditec (0DHC) was downgraded to a Hold Rating at Barclays

Susannah Ludwig

Bernstein

€50.55→€31

Hold

12.48%

Upside

Downgraded

01/26/26

Carl Zeiss Meditec (0DHC) was downgraded to a Hold Rating at Bernstein

Richard Felton

Goldman Sachs

€54→€42

Hold

52.39%

Upside

Downgraded

01/23/26

Carl Zeiss Meditec: Slowing Growth, Limited Upside and Leadership Uncertainty Justify Hold Rating

Falko Friedrichs

Deutsche Bank

€44→€34

Hold

23.37%

Upside

Reiterated

01/23/26

Deutsche Bank Sticks to Their Hold Rating for Carl Zeiss Meditec (0DHC)

Jack Reynolds-Clark

RBC Capital

€47

Hold

70.54%

Upside

Reiterated

01/22/26

RBC Capital Sticks to Its Hold Rating for Carl Zeiss Meditec (0DHC)

Graham Doyle

UBS

€53

Hold

92.31%

Upside

Reiterated

01/22/26

Carl Zeiss Meditec (0DHC) Gets a Hold from UBS

Sam England

Berenberg Bank

€35

Hold

27.00%

Upside

Reiterated

01/22/26

Carl Zeiss Meditec (0DHC) Gets a Hold from Berenberg Bank

Oliver Reinberg

Kepler Capital

€46

Hold

66.91%

Upside

Reiterated

01/22/26

Kepler Capital Keeps Their Hold Rating on Carl Zeiss Meditec (0DHC)

David Adlington

J.P. Morgan

€35.1

Sell

27.36%

Upside

Reiterated

01/22/26

J.P. Morgan Sticks to Its Sell Rating for Carl Zeiss Meditec (0DHC)

Unknown Analyst

DZ BANK AG

Not Ranked

DZ BANK AG

Hold

―

Reiterated

12/16/25

Alexander Galitsa

Hauck & Aufhaeuser

€70→€68

Buy

146.73%

Upside

Reiterated

08/08/25

Carl Zeiss Meditec (0DHC) Receives a Buy from Hauck & Aufhaeuser

Dylan Van Haaften

Stifel Nicolaus

€60→€50

Hold

81.42%

Upside

Reiterated

08/05/25

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Jonathon Unwin

Barclays

€49→€32

Hold

16.11%

Upside

Downgraded

02/02/26

Carl Zeiss Meditec (0DHC) was downgraded to a Hold Rating at Barclays

Susannah Ludwig

Bernstein

€50.55→€31

Hold

12.48%

Upside

Downgraded

01/26/26

Carl Zeiss Meditec (0DHC) was downgraded to a Hold Rating at Bernstein

Richard Felton

Goldman Sachs

€54→€42

Hold

52.39%

Upside

Downgraded

01/23/26

Carl Zeiss Meditec: Slowing Growth, Limited Upside and Leadership Uncertainty Justify Hold Rating

Falko Friedrichs

Deutsche Bank

€44→€34

Hold

23.37%

Upside

Reiterated

01/23/26

Deutsche Bank Sticks to Their Hold Rating for Carl Zeiss Meditec (0DHC)

Jack Reynolds-Clark

RBC Capital

€47

Hold

70.54%

Upside

Reiterated

01/22/26

RBC Capital Sticks to Its Hold Rating for Carl Zeiss Meditec (0DHC)

Graham Doyle

UBS

€53

Hold

92.31%

Upside

Reiterated

01/22/26

Carl Zeiss Meditec (0DHC) Gets a Hold from UBS

Sam England

Berenberg Bank

€35

Hold

27.00%

Upside

Reiterated

01/22/26

Carl Zeiss Meditec (0DHC) Gets a Hold from Berenberg Bank

Oliver Reinberg

Kepler Capital

€46

Hold

66.91%

Upside

Reiterated

01/22/26

Kepler Capital Keeps Their Hold Rating on Carl Zeiss Meditec (0DHC)

David Adlington

J.P. Morgan

€35.1

Sell

27.36%

Upside

Reiterated

01/22/26

J.P. Morgan Sticks to Its Sell Rating for Carl Zeiss Meditec (0DHC)

Unknown Analyst

DZ BANK AG

Not Ranked

DZ BANK AG

Hold

―

Reiterated

12/16/25

Alexander Galitsa

Hauck & Aufhaeuser

€70→€68

Buy

146.73%

Upside

Reiterated

08/08/25

Carl Zeiss Meditec (0DHC) Receives a Buy from Hauck & Aufhaeuser

Dylan Van Haaften

Stifel Nicolaus

€60→€50

Hold

81.42%

Upside

Reiterated

08/05/25

Stocks with the Highest Top Analyst Consensus in the General Sector

xxx

Find stocks in the General sector that are highly recommended by Top Performing Analysts.

AFX Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AFX has received 8 Buy Ratings, 35 Hold Ratings, and 3 Sell Ratings. AFX average Analyst price target in the past 3 months is 39.46.

Each month's total comprises the sum of three months' worth of ratings.

AFX Financial Forecast

AFX Earnings Forecast

Next quarter’s earnings estimate for AFX is €0.23 with a range of €0.04 to €0.41. The previous quarter’s EPS was €0.59. AFX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.89% of the time in the same period. In the last calendar year AFX has Performed in-line its overall industry.

AFX Sales Forecast

Next quarter’s sales forecast for AFX is €471.38M with a range of €463.89M to €487.83M. The previous quarter’s sales results were €1.18B. AFX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 53.24% of the time in the same period. In the last calendar year AFX has Performed in-line its overall industry.

AFX Stock Forecast FAQ

What is DE:AFX’s average 12-month price target, according to analysts?

Based on analyst ratings, Carl Zeiss Meditec’s 12-month average price target is 39.46.

What is DE:AFX’s upside potential, based on the analysts’ average price target?

Carl Zeiss Meditec has 43.18% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Carl Zeiss Meditec a Buy, Sell or Hold?

Carl Zeiss Meditec has a consensus rating of Hold, which is based on 0 buy ratings, 9 hold ratings and 1 sell ratings.

What is Carl Zeiss Meditec’s share price target?

The average share price target for Carl Zeiss Meditec is 39.46. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €53.00 ,and the lowest forecast is €31.00. The average share price target represents 43.18% Increase from the current price of €27.56.

What do analysts say about Carl Zeiss Meditec?

Carl Zeiss Meditec’s analyst rating consensus is a Hold. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of Carl Zeiss Meditec?

To buy shares of DE:AFX, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Carl Zeiss Meditec (AFX) Stock Forecast & Price Target

AFX Analyst Ratings

AFX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

AFX Analyst Recommendation Trends

AFX Financial Forecast

AFX Earnings Forecast

AFX Sales Forecast

AFX Stock Forecast FAQ

Detailed List of Analyst Forecasts